US Patent 11603405 Anti-CD3 antibodies and uses thereof

Is a

Patent

Patent attributes

Patent Applicant

Janssen Biotech

Current Assignee

Janssen Biotech

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11603405

Date of Patent

March 14, 2023

Patent Application Number

16418082

Date Filed

May 21, 2019

Patent Citations

‌

US Patent 10465006 Humanized or chimeric CD3 antibodies

Patent Primary Examiner

‌

Michael Szperka

The present invention relates to antibodies that specifically bind CD3. The present invention relates to antibodies that specifically bind PSMA. The present invention relates to antibodies that specifically bind CD3 and PSMA. The present invention relates to antibodies that specifically bind IL1RAP. The present invention relates to antibodies that specifically bind CD33. The present invention relates to antibodies that specifically bind CD3 and IL1RAP. The present invention relates to antibodies that specifically bind CD3 and CD33. The present invention relates to antibodies that specifically bind TMEFF2. The present invention relates to antibodies that specifically bind CD3 and TMEFF2. The present invention relates to fragments of the antibodies, polynucleotides encoding the antibodies or fragments thereof, and methods of making and using the same.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

US Patent 11603405 Anti-CD3 antibodies and uses thereof

Contents

Patent attributes

Timeline

Further Resources

References

Find more entities like US Patent 11603405 Anti-CD3 antibodies and uses thereof